Background: Mutations of the autoimmune regulator gene (AIRE), located on chromosome 21q22.3, are recognized as the cause of a rare monogenic organ-specific autoimmune disorder called autoimmune polyglandular syndrome type 1 (APS-1). Three major components of this syndrome include chronic mucocutaneous candidiasis (CMC), hypoparathyroidism, and adrenocortical failure.

Case presentation: We report a 19-year-old girl, who was born in an Iranian Muslim family with a clinical diagnosis of APS-1. To identify the causative mutation, a direct sequencing of the entire AIRE gene sequence was performed by Sanger sequencing method.

Three distinct variants were discovered, including c.1095 +2 T > A, c.1197 T > C (rs1800521) and c.1578 T > C (rs1133779), in intron 9, exons 10 and 14 of the AIRE gene, respectively.

Conclusions: To the best of our knowledge, this is the first report of an Iranian Muslim APS-1 patient with combination of these variations. In addition, the effect of c.1095 +2 T > A mutation on AIRE mRNA expression was reported for the first time. This study expands the diversity of variants that could cause APS-1. More genetic studies are required to determine the exact frequency of these variants and their diagnostic significance.

Keywords: Single nucleotide variation, APS-1, AIRE gene, Mutation, APECED
different ethnic groups [12, 13]. It has been suggested that mutation in different regions of the AIRE gene has various results on the function of the AIRE protein with a currently poorly-described mechanism [7, 9, 14]. In this article, we report three AIRE variations in a patient with APS-1 from an Iranian Muslim family.

**Case presentation**

**Patient**
The patient was a 19-year-old girl who was born in an Iranian Muslim family. She was referred to our center (Shariati hospital, Tehran, Iran) due to her low back pain and multiple vertebral fragility fractures. Other important complaints of her were including primary amenorrhea, peri-oral, and acral paresthesia, blurred vision, and also foreign body sensation. She did not have any signs or symptoms of malabsorption.

**Past medical history**
Her past medical history was significant for hypocalcemia-induced generalized tonic-clonic seizures (three episodes), when she was at the age of 6, due to hypoparathyroidism. Consequently, she received calcitriol and calcium supplementation, but her compliance was poor. At the age of 7, she was diagnosed with alopecia areata. She was suffering from asthma at the same time, for which she used salbutamol and montelukast. Being short in stature at the age of 13.5 years old (height = 134 cm, standard deviation score (SDS) = −3.8), she was evaluated whereby the growth hormone (GH) deficiency was revealed; however, due to financial problems, she could not afford the costs and therefore did not follow through the GH treatment. She had also been experiencing a history of CMC involving oral cavity and nails since the age of 14 years old. Her other complaint was dry eye symptoms for 2 years, and for this reason she have been receiving artificial tears. She had also taken a course of oral acyclovir with the diagnosis of herpes simplex keratopathy. She was not on a regular follow-up before being referred to our center.

**Family history**
Her family history was remarkable for her parents’ consanguineous marriage, and also her sister death at the age of 14 years old, with no definitive diagnosis. Her sister had a history of blindness due to endophthalmitis and her symptoms before death were weakness, loss of appetite, fever, nausea, and vomiting. The other patient’s siblings were healthy (two 30 and 26-year-old brothers and a 28-year-old sister). The patient’s pedigree chart is illustrated in Fig. 1.

**Managements in our center**
Due to hypoparathyroidism (calcium = 6.6 mg/dl, Phosphorus = 7.8 mg/dl, iPTH = < 8 pg/ml), an adequate dose of calcium (3 g/day elemental calcium in divided doses) and calcitriol (0.5 micrograms daily) supplementation were initiated, with sevelamer (800 mg three times per day) being later added, in regard with the inadequate phosphorus control. The patient complaint of primary amenorrhea and her physical examination revealed delayed puberty (Tanner stage 3 for breast development and stage 2 for pubic hair). With the diagnosis of premature ovarian failure (FSH = 64.5 IU/l, LH = 45.6 IU/l, prolactin: 35 ng/ml), hormone replacement therapy was initiated (0.625 mg conjugated equine estrogens for 21 days and 5 mg medroxyprogesterone acetate for 10 days). Levothyroxine (50 micrograms daily), was also added due to subclinical hypothyroidism (TSH = 9.3 µIU/ml, TT4 = 9.8 µg/dl, TT3 = 166 ng/dl, antithyroid peroxidase antibody = positive). Adrenal insufficiency was ruled out by the Cosyntropin test (baseline ACTH = 60 pg/ml, baseline cortisol = 11 µg/dl, peak cortisol = > 50 µg/dl; note that adrenal autoantibodies were not checked due to the absence of these tests in Iran). Because of short stature (height = 137 cm, SDS = −4), GH test was performed, which confirms GH deficiency (IGF1 = 66 ng/ml [NL: 198–551], clonidine test: peak GH = 2.8 mIU/l). GH treatment was offered, however, she did not take the GH treatment due to the financial problems. Her liver enzymes were elevated: ALT = 108 IU/l (NL: Up to 32), AST = 84 IU/l (NL: Up to 31), and ALP = 409 IU/l (NL: 64–306). The hepatitis viral markers were negative and serum protein electrophoresis demonstrated an elevation of serum IgG. Liver biopsy was performed, which indicated a chronic hepatitis (modified histology activity index grading: 9 [15], modified histology activity index staging: 3 [15]), compatible to autoimmune hepatitis. The patient was then referred to a gastroenterologist for

![Fig. 1 The patient’s pedigree chart. *Mutation screening was done for the patient and her parents](image)
further work-up and treatment. The other laboratory tests were normal, ruling out celiac disease (anti-endomysial antibody = negative), diabetes mellitus, and B12 deficiency.

Ophthalmologic consultation was done, because of foreign body sensation and blurred vision, which showed dry eyes and keratopathy due to a limbal stem cell deficiency. Cyclosporine eye drop, vitamin A eye ointment, fluorometholone eye drop, and artificial tears were initiated, and later inferior punctum closure was performed for the patient in order to improve her dry eyes.

Multiple vertebral fractures, which result in spine deformity, were evident in her spine x-ray. Bone mineral densitometry (BMD) was performed which revealed osteoporosis; height adjusted lumbar spine, femoral neck, and total hip BMD Z-Score were −5.80, −4.07, and −2.80, respectively [16]. Other imaging studies including brain computed tomography (CT) and abdominopelvic ultrasound were normal, except for an infantile uterus and small ovaries in ultrasound.

The patient’s clinical findings are summarized in Table 1. With the diagnosis of APS-1, genetic testing was performed, which indicated the AIRE gene variations.

### Mutation analysis

The DNA was extracted from peripheral blood lymphocyte, using the phenol-chloroform method. Primers encompassing the AIRE gene region were previously described [17]. Primer sequences and polymerase chain reaction (PCR) conditions for the amplification of the AIRE gene region are listed in Table 2. The PCR was performed by thermal cycler (BIO RAD, MJ mini thermal cycler, model: PTC-1148, made in Singapore) and the PCR protocol was set as follows: 5 min for the initial denaturation at 95 °C, 35 cycles of amplification (each cycle consisted of 30 s at 95 °C, 30 s of annealing at a specific temperature for each of the primer pairs (Table 2) and 30 s of extension at 72 °C, followed by the final extension at 72 °C for 5 min. Direct sequencing (Sanger sequencing method) was used for identifying the probable variation of each exon-intron. Chromas software (version 2.6.2) and National Center for Biotechnology Information (NCBI) gene databases (https://www.ncbi.nlm.nih.gov/) such as Basic Local Alignment Search Tool (BLAST), Clinical Variation (ClinVar), and Single Nucleotide Polymorphism database (dbSNP) were used for the sequence analysis.

### Gene expression analysis

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples by the density gradient centrifugation method via Ficoll-Paque PLUS (GE life science). Whole Ribonucleic Acids (RNAs) were extracted from the PBMCs using Trizol reagent. The total messenger RNAs (mRNAs) were reversely transcribed into complementary DNAs (cDNAs) by random primers (K1622, Thermo scientific). Real-time PCR was performed on the LightCycler® 96 System (Roche) using SYBR Green and the specific primer for AIRE mRNA. The hypoxanthine guanine phosphoribosyl transferase (HPRT) was used as the internal control. The sequences of primers for real-time PCR are reported in Table 3. All samples were run in triplicates. The PCR reaction was performed by 10 μl fast start essential SYBR Green Master (Roche), 0.8 μl forward primer, 0.8 μl reverse primer, 6 μl cDNA (1/10 diluted), and 2.4 μl PCR grade water, with an initial denaturation step of 10s at 95 °C, 40 cycles

### Table 1 Patient’s clinical findings

| Diagnosis                              | Age of presentation/diagnosis (year) | Presentation                                      | Treatments                                                                                       |
|----------------------------------------|-------------------------------------|--------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Hypoparathyroidism                      | 6                                   | Generalized tonic-clonic seizures                | Calcitriol and calcium, later sevelamer was added                                              |
| Alopecia areata                         | 7                                   | Hair loss                                        | Intralesional corticosteroid injections                                                        |
| Asthma                                 | 7                                   | Dyspnea                                          | Salbutamol and montelukast                                                                     |
| GH deficiency                          | 13.5                                | Short stature                                     | No treatment                                                                                    |
| Chronic mucocutaneous candidiasis      | 14                                  | Oral cavity and nails candidiasis                | Course of fluconazole                                                                          |
| APS1-associated keratopathy            | 17                                  | Dry eye symptoms                                  | Artificial tears, later cyclosporine eye drop, vitamin A eye ointment and fluorometholone eye drop were added and finally inferior punctum closure was performed |
| Osteoporosis, vertebral fragility fractures | 19                               | Low back pain                                    | Hormone replacement therapy                                                                   |
| Premature ovarian failure               | 19                                  | Primary amenorrhea                                | Hormone replacement therapy                                                                   |
| Subclinical hypothyroidism             | 19                                  | Abnormal thyroid function tests                   | Levothyroxine                                                                                  |
| Autoimmune hepatitis                   | 19                                  | Abnormal liver function tests                     | Referred to a gastroenterologist                                                              |
| Dental enamel hypoplasia               | –                                   | Dental decay                                      | Dental care                                                                                    |
at 95 °C for 5 s, and 60 °C for 30s. The fold changes were determined as $2^{-\Delta\Delta CT}$.

**Mutation and gene expression analysis results**
Sequencing the whole coding region and the exon-intron borders of the AIRE gene demonstrated three variants in the patient: a homozygous mutation in intron 9 (c.1095 + 2 T > A); a homozygous single nucleotide synonymous variant in exon 10 (c.1197 T > C, rs1800521); and a homozygous single nucleotide synonymous variant in exon 14 (c.1578 T > C, rs1133779).

In addition, carrier screening was carried out in both parents, which confirmed heterozygous c.1095 + 2 A mutation (Fig. 2).

In silico analysis using Human Splicing Finder (http://www.umd.be/HSF/) [18] has suggested that c.1095 + 2 T > A variation may result in alteration of an exonic splicing enhancer (ESE) site causing potential alteration of splicing.

**Discussion and conclusions**
To date, many APS-1-causing mutations have been identified in the AIRE gene across different ethnic groups.
The Iranian Jewish population is well-known for carrying a founder AIRE gene mutation (Y85C) which causes a tyrosine to a cysteine change in the HSR domain [14]. Other reported AIRE mutations in the Iranian population have been R139X, R257X, K50NfsX168, and L323SfsX51 [12].

In line with the recessive mode of the inheritance of APS-1, most mutations of the AIRE gene are homozygous or compound heterozygous [7, 9, 19, 20]. Pathogenic mutations spread over the entire coding sequence of the AIRE gene where at least four mutational hot spots including exons 2, 6, 8, and 10 have been reported [11]. The proband in our study had one silent polymorphism in the hot spot exon 10 and one silent polymorphism in exon 14. Moreover, the promoter region or the intronic sequence mutation with an impact on the transcription and/or RNA splicing is possible [11, 12]. Our proband had one intronic mutation with a probable RNA splicing effect.

Two variants, c.1197 T > C and c.1578 T > C, which were observed in our patient, were reported for the first time in 1998 [21–23]. These two synonymous variants, one in exon 10 (proline-rich region) and the other in exon 14 (near one of the four interspersed LXXLL motifs) do not change the amino acid type at the protein level and are unlikely to have functional implications. In other words, the substitution of the T nucleotide in position 1197 to C (c.1197 T > C) does not change alanine amino acid in position 399 (p.Ala399=); similarly, the substitution of the T nucleotide in position 1578 to C (c.1578 T > C) does not alter aspartate amino acid in position 526 of the AIRE protein (p.Asp526=). Cetani et al. reported a 38-year-old Italian APECED woman who carried a G228 W mutation and three common silent heterozygous polymorphisms (588 C/T, S196S; 1197 T/C, A399A; and 1578 T/C D526D) [11]. Sun et al. also presented a 15-year-old Chinese APS-1 patient with c.57 T > C, c.588C > T, c.834C > G, c.1197 T > C, and c.1578 T > C SNPs [24]. These findings which are in line with our results highlight the fact that the two SNPs
The substitution of the T nucleotide in the second nucleotide of intron 9 to A (c.1095 + 2 T > A) is located in a region between PHD1 and PRR. This mutation occurs in the conserved splice donor sequence and leads to a change in the wild type donor site, affecting splicing [12]. Recently, Seifi-Alan et al. reported an Iranian Muslim family with the same mutation in intron 9 (c.1095 + 2 T > A) in which the parents were both heterozygous for this mutation. The 9-year-old proband in this report suffered from APS-1 (CMC, Addison’s disease, hypoparathyroidism, and hypothyroidism) [12]. The proband in our study had the same phenotype (with the exception of late onset CMC and the lack of Addison’s disease in our case), suggesting that c.1095 + 2 T > A may be regarded as a founder mutation in Iranian population, which cause APS-1 development. The late onset CMC and the lack of adrenal insufficiency in our case may be due to the fact that even patients with the same AIRE mutations present with a wide range of clinical manifestations and different courses of the disease [13]. According to Perheentupa et al., who followed up 91 APS1 patients up to 50 years, the initial manifestation of APS1 appeared at age 0.2–18 years. Among the main signs of APS1, CMC, hypoparathyroidism, and adrenal insufficiency were the presenting features in 60, 32, and 5% of patients, respectively. The CMC, hypoparathyroidism, and adrenal insufficiency affected 100, 87, and 81% of APS1 patients respectively by the time they were 40 years old [25]. The presenting feature in our case was hypoparathyroidism (age of 6) and later at age of 14, CMC was detected which is congruent with some cases of Perheentupa report. Our patient did not have adrenal insufficiency. Nevertheless, as we did not check anti-adrenal autoantibodies, the adrenal autoimmunity was not excluded. The vertebral fragility fractures in our case was justified by a combination of GH and estrogen deficiency.

Although the main expression of AIRE occurs in the medullary tissue of thymus [23], the dendritic cells of the blood also express this gene [26, 27]. Therefore, we examined the mRNA level of this gene in the PBMCs to test the effect of this splicing site mutation on the expression level. Our study indicated an up-regulation of AIRE expression in the patient with a homozygous c.1095 + 2 T > A mutation in comparison to patient’s parents with heterozygous mutation and other siblings (Fig. 3). The AIRE mRNA level was not reported in Seifi-Alan et al.’s report [12], and as a result, we could not compare this finding to pervious results. However, Björses et al. reported 13 Iranian Jews with APS-1 who had an A374G (Y85C) mutation in exon 2 with a transcriptional activity of 115% of the wild-type AIRE. Transcriptional activity of the Y85C mutation was in contrast to other mutations with low or no transcriptional activity reported by Björses et al. [7]. The mechanism suggested for this finding is that while the Y85C mutant AIRE protein has a correct length, it has a significantly shorter half-life and as a result, it rapidly deteriorates [14]. A similar mechanism may explain a higher mutant AIRE mRNA expression level we found here. Further studies are required to examine the effect of this intronic mutation (c.1095 + 2 T > A) on the function and stability of the AIRE protein and its cellular consequences. The expression level of the AIRE mRNA was assessed in PBMCs in our study, not at the site of its actual transcriptional activity located at thymus. Therefore, further investigations in the thymic tissue are required to confirm our results.

In conclusion, we identified three previously reported AIRE gene variations in an Iranian Muslim APS-1 patient. Furthermore, the association between c.1095 + 2 T > A mutation and APS-1 disease was confirmed in this report. Finally, AIRE gene expression analysis was performed, which indicated the functional impact of this variation for the first time. This study expands the diversity of variants that could cause APS-1. In addition to diagnostic utility, this information will help us better understand the pathophysiology of APS-1. More genetic studies are required to determine the frequency of these variants and their diagnostic credibility.

**Acknowledgements**

We appreciate the patient and his family’s cooperation in this case report.

**Authors’ contributions**

SMSJ, SE and AKH wrote the manuscript. AS and MMA supervised the management of the case and approved the manuscript. AS and SMSJ managed the patient and finalized the manuscript. MMA, SE, and AKH performed the genetic studies. All authors read and approved the final manuscript.

**Funding**

No funding was received.

**Abbreviations**

ACTH: Adrenocorticotropic Hormone; AIRE: Autoimmune Regulator gene; ALP: Alkaline Phosphatase; ALT: Alanine Aminotransferase; APECED: Autoimmune Polyendocrinopathy-Candidiasis–Ectodermal Dystrophy/Dysplasia; APS-1: Autoimmune Polyglandular Syndrome type 1; AST: Aspartate Aminotransferase; BLAST: Basic Local Alignment Search Tool; BMD: Bone Mineral Densitometry; cDNAs: Complementary DNAs; ClinVar: Clinical Variation; CMC: Chronic Mucocutaneous Candidiasis; CT: Computed Tomography; dbSNP: Single Nucleotide Polymorphism database; ESE: Exonic Splicing Enhancer; FSH: Follicle stimulating hormone; GH: Growth Hormone; HPRT: Hypoxanthine Guanine Phosphoribosyl Transferase; HSR: Homogeneously Staining Region; IGF1: Insulin like growth factor 1; IgG: Immunoglobulin G; iPTH: Intact Parathyroid hormone; LH: Luteinizing Hormone; mRNAs: Messenger RNAs; NCBI: National Center for Biotechnology Information; NLS: Nuclear Localization Signal; PBMCs: Peripheral Blood Mononuclear Cells; PCR: Polymerase Chain Reaction; PHD: Plant Homeodomain; PPR: Proline-Rich Region; RNAs: Ribonucleic Acids; SDS: Standard Deviation Score; TSH: Thyroid Stimulating Hormone; TT3: Total Thyroxine; TT4: Total Triiodothyronine.
Availability of data and materials
Not applicable.

Ethics approval and consent to participate
All procedures performed in the research involving human participants were in accordance with the ethical standards of Tehran University of Medical Sciences and with the Helsinki declaration. Informed consent was obtained from all individual participants included in the study.

Consent for publication
An informed written consent was obtained from the patient for the publication of this case report. A copy of written consent is available for the journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. 2. Cell therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran university of Medical Sciences, Tehran, Iran. Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Received: 23 December 2018 Accepted: 2 August 2019 Published online: 16 August 2019

References
1. Ahonen P, Mylläriemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune Polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829–36.
2. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison’s disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore). 1981;60:355–62.
3. Peterson P, Pitkänen J, Sillanpää N, Krohn K. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin Exp Immunol. 2004;135:348–57.
4. Betterle C, Greggio NA, Volpato M. Autoimmune Polyendocrine syndrome type 1. J Clin Endocrinol Metab. 1998;83:1049–55.
5. Capaldo D, De Martino L, Giardino G, Di Mase R, Di Donato I, Parenti G, et al. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: insights into genotype-phenotype correlation. Int J Endocrinol. 2012;2012:353250.
6. Halonen M, Eskeli P, Myhr A-G, Perheentupa J, Husebye ES, Kämpe O, et al. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab. 2002;87:2568–74.
7. Bijnens P, Halonen M, Palvimo JJ, Kolmer M, Aaltonen J, Ellonen P, et al. Mutations in the AIRE gene: effects on subcellular localization and transactivation function of the autoimmune Polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet. 2000;66:378–92.
8. Buži F, Badolato R, Mazza C, Giliani S, Notarangelo LD, Radetti G, et al. Autoimmune Polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review diagnostic criteria? J Clin Endocrinol Metab. 2003;88:1346–8.
9. Brusserud Ø, Oftedal BE, Wolff AB, Husebye ES. AIRE-mutations and autoimmune disease. Curr Opin Immunol. 2016;43:8–15.
10. Sparks AE, Chen C, Brezlin MB, Lan MS. Functional domains of autoimmune regulator (AIRE) modulate INS-VNTR transcription in human thyimic epithelial cells. J Biol Chem. 2016;291:11313–22.
11. Cetani F, Barbesino G, Borsari S, Pardi E, Clanferreti L, Pinchera A, et al. A novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune Polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly Copseggregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2001;86:4747–52.
12. Seifi-alian M, Shamsi R, Setodcheh A, Sayarifar F, Aghasi P, Kompani F, et al. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: report of three cases from Iran. J Pediatr Endocrinol Metab. 2016;29:79–83.
13. Weiler FG, Dias-da-Silva MR, Lazarriti-Castro M. Autoimmune polyendocrine syndrome type 1: case report and review of literature. Arq Bras Endocrinol Metabol. 2012;56:54–66.
14. Ramsey C, Bukinsky A, Petlonen L. Systematic mutagenesis of the functional domains of AIRE reveals their role in intracellular targeting. Hum Mol Genet. 2002;11:3299–308.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groot J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:569–9.
16. Zemel BS, Kallowarf HJ, Gilanzan V, Lappe JM, Oberfield S, Shepherd JA, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011;96:3160–9.
17. Pearce SH, Cheetham T, Irrie H, Vaidya B, Barnes ND, Bilous RW, et al. A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type 1. Am J Hum Genet. 1998;63:1675–84.
18. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004;11:377–94.
19. Cervato S, Marinello B, Lazzarotto F, Morlini L, Zanchetta R, Radetti G, et al. Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clin Endocrinol. 2009;70:421–8.
20. Meloni A, Perniolo R, Faà V, Corvaglia E, Cao A, Rossetelli MC. Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from southern Italy. J Clin Endocrinol Metab. 2002;87:841–6.
21. Wang CY, Davoodi-Semirami A, Huang W, Connor E, Shi JD, She JX. Characterization of mutations in patients with autoimmune polyglandular syndrome type 1 (APS1). Hum Genet. 1998;103:681–5.
22. Scott HS, Heino M, Peterson P, Mittaz L, Lalioti MD, Betterle C, et al. Common mutations in autoimmune Polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol. 1998;12:1112–9.
23. Heino M, Peterson P, Kudoh J, Shimizu N, Antonarakis SE, Scott HS, et al. APECED mutations in the autoimmune regulator (AIRE) gene. Hum Mutat. 2001;18:205–11.
24. Sun Y, He Y, Li X. Clinical analysis and autoimmune regulator gene mutation evaluation of autoimmune polyendocrinopathy syndrome type I in a family: a report of one case. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18:147–51.
25. Betterle C. Autoimmune Polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2006;91:2943–50.
26. Kogawa K, Nagafuchi S, Katsuta H, Tamiya S, Sakai Y, et al. Expression of AIRE gene in peripheral monocyte/dendritic cell lineage. Immunol Lett. 2002;80:195–9.
27. Nagafuchi S, Katsuta H, Koyanagi-Katsuta R, Yamasaki S, Inoue Y, Shimoda K, et al. Autoimmune regulator (AIRE) gene is expressed in human activated CD4+ T-cells and regulated by mitogen-activated protein kinase pathway. Microbiol Immunol. 2006;50:979–87.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedicalcentral.com/submissions